ketastesic vet 100 mg/ml injektionsvätska, lösning
zoetis finland oy - ketaminhydroklorid - injektionsvätska, lösning - 100 mg/ml - ketaminhydroklorid 115,36 mg aktiv substans - ketamin - hund, häst, katt
promon vet. 5 mg tablett
zoetis finland oy - medroxiprogesteronacetat - tablett - 5 mg - medroxiprogesteronacetat 5 mg aktiv substans; sackaros hjälpämne; laktosmonohydrat hjälpämne - medroxiprogesteron - hund, katt
promon vet. 50 mg/ml injektionsvätska, suspension
zoetis finland oy - medroxiprogesteronacetat - injektionsvätska, suspension - 50 mg/ml - medroxiprogesteronacetat 50 mg aktiv substans; propylparahydroxibensoat hjälpämne; metylparahydroxibensoat hjälpämne - medroxiprogesteron - hund, katt
cydectin vet. 1 mg/ml oral lösning
zoetis finland oy - moxidektin - oral lösning - 1 mg/ml - propylenglykol hjälpämne; butylhydroxitoluen hjälpämne; bensylalkohol hjälpämne; moxidektin 1 mg aktiv substans - moxidektin - får
terramycin vet. 20 % oralt pulver
zoetis finland oy - oxitetracyklinhydroklorid - oralt pulver - 20 % - laktosmonohydrat hjälpämne; oxitetracyklinhydroklorid 220 mg aktiv substans - oxitetracyklin - fjäderfä, nöt, pälsdjur, svin
boviseal vet 2,6 g intramammär suspension
zoetis finland oy - vismutsubnitrat, tungt - intramammär suspension - 2,6 g - vismutsubnitrat, tungt 2,6 g aktiv substans - Övriga produkter för spenar och juver - nöt
fludeomap 250 mbq/ml injektionsvätska, lösning
curium finland oy - fludeoxiglukos(f-18) - injektionsvätska, lösning - 250 mbq/ml - fludeoxiglukos(f-18) 250 mbq aktiv substans
docetaxel mylan
mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastiska medel - behandling av bröstcancer, speciella former av lungcancer (icke-småcellig lungcancer), prostatacancer, magcancer eller huvud och nackcancer.
teriparatide sun
sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - calciumhomeostas - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.
faslodex
astrazeneca ab - fulvestrant - bröst-neoplasmer - endokrin terapi, anti-östrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausala kvinnor, kombinationsbehandling med palbociclib bör kombineras med en luteinizing hormone releasing hormone (gnrh) agonist.